Continue to the content

COVID-19 Repository of References

Repository of References

  • EMA: reminder of risk of serious side effects with chloroquine and hydroxychloroquine
  • IJWD: The Dermatologist’s Perspective: Why is COVID-19 mortality lower in females than males?


Abbreviations used:
EMA = European Medicines Agency
IJWD = International Journal of Women’s Dermatology

EADV = European Academy of Dermatology and Venereology

SPIN Recommandation for the EADV COVID-19 Resource Center

The available data on past and present outbreaks of Coronavirus infections (SARS, MERS, COVID-19) suggest that immunosuppressed patients are not at increased risk for severe manifestations and complications of COVID-19 compared to the general population.

Immunosuppressive and immunomodulatory drugs (human interleukin-1 receptor antagonist and anti-interleukin-6) may potentially control the “cytokine storm” associated with a poorer outcome in these patients.

Thus, patients with cutaneous immune-mediated diseases (including psoriasis, atopic dermatitis, and hidradenitis suppurativa) can, in general (and subject to individual consideration with the prescriber), continue their treatment during the COVID-19 outbreak. This would prevent disease flares that can contribute to increasing patient burden, disability, poor quality of life, and healthcare usage.

Withholding immunosuppressive (e.g. methotrexate, cyclosporine) or biologic treatment in patients with active COVID-19 infection is generally recommended. Starting these treatments in the event of active infections is contraindicated.

If patients develop symptoms consistent with COVID-19 infection, it
is advisable that such treatments are paused. We recognize that →

some comorbidities associated with psoriasis, hidradenitis suppurativa and atopic dermatitis (obesity, diabetes, hypertension, cardiovascular disease, chronic lung disease, asthma), and in those aged 60 years and older, worsen the prognosis of COVID-19 infection.

If patients live in areas with a high incidence of COVID-19 infection, or are close contacts of confirmed cases, individual consideration should be given to temporary discontinuation of some therapies considering factors such as age or comorbidities.

Currently we have no data regarding the impact of systemic psoriasis therapies (or therapies for atopic dermatitis and hidradenitis suppurativa) on susceptibility to or severity of COVID-19 infection.

Thus, any guidance is based on previous clinical experience and an understanding of the mechanisms of action of our therapies. The TF recommends that all patients with these diseases who have either suspected or confirmed COVID-19 infection are entered into the relevant registries established to address this lack of data.s